EP Patent

EP3597646B1 — Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Assigned to Gilead Sciences Inc · Expires 2023-06-21 · 3y expired

What this patent protects

Patent listed against lenacapavir-sodium.

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: EP3597646B1
Jurisdiction: EP
Classification: —
Expires: 2023-06-21
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.